KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

• Status: Recruiting
• Trial end date: 2025-07-24
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kartos Therapeutics, Inc.
• Collaborator: Telios Pharma, Inc.

Criteria

Inclusion Criteria:

• Confirmed diagnosis of primary MF, post-PV MF, or post-ET MF, (WHO 2016)

• ECOG ≤ 2

• Cohort 1 and Cohort 2: R/R following JAK inhibitor treatment

• Cohort 3: patients who are intolerant to JAK inhibitor treatment

Exclusion Criteria:

• Prior treatment with MDM2 inhibitors or p53-directed therapies

• Prior treatment with a BCR-ABL, phosphoinositide 3-kinase (PI3k), mammalian target of rapamycin (mTOR), bromodomain and extraterminal domain (BET), histone deacetylase (HDAC), or spleen tyrosine kinase (Syk) inhibitor

• Prior splenectomy

• Splenic irradiation within 3 months prior to the first dose of study treatment

• Clinically significant thrombosis within 3 months of screening

• Grade 2 or higher QTc prolongation